Chapter 1.  Imatinib Drug Market– Scope & Methodolog
1.1    Market Segmentation
1.2    Assumptions
1.3    Research Methodology
1.4    Primary Sources
1.5    Secondary Sources
Chapter 2. Imatinib Drug Market– Executive Summary
2.1    Market Size & Forcast – (2023 – 2030) ($M/$Bn)
2.2    Key Trends & Insights
2.3    COVID-19 Impact Analysis
       2.3.1    Impact during 2023 – 2030
       2.3.2    Impact on Supply – Demand
Chapter 3.  Imatinib Drug Market– Competition Scenario
3.1    Market Share Analysis
3.2    Product Benchmarking
3.3    Competitive Strategy & Development Scenario
3.4    Competitive Pricing Analysis
3.5    Supplier - Distributor Analysis
Chapter 4.  Imatinib Drug Market- Entry Scenario
4.1     Case Studies – Start-up/Thriving Companies
4.2     Regulatory Scenario - By Region
4.3    Customer Analysis
4.4     Porter's Five Force Model
       4.4.1     Bargaining Power of Suppliers
       4.4.2     Bargaining Powers of Customers
       4.4.3    Threat of New Entrants
       4.4.4    .Rivalry among Existing Players
       4.4.5    Threat of Substitutes
Chapter 5. Imatinib Drug Market- Landscape
5.1     Value Chain Analysis – Key Stakeholders Impact Analysis
5.2    Market Drivers
5.3    Market Restraints/Challenges
5.4    Market Opportunities
Chapter 6. Imatinib Drug Market- By Drug Formulation
6.1    Capsules
6.2    Tablets
Chapter 7. Imatinib Drug Market- By Application Type
7.1    Philadelphia Positive Chronic Myeloid Leukemia
7.2    Hyper-Eosinophilic Syndrome (HES)
7.3    Myelodysplastic Syndrome (MDS)
7.4    Myeloproliferative Diseases (MPD)
7.5    Gastrointestinal Stromal Tumors (GIST)
7.6    Others
Chapter 8.  Imatinib Drug Market– By Region
8.1    North America
8.2    Europe
8.3    Asia-Pacific
8.4    Latin America
8.5    The Middle East
8.6    Africa
Chapter 9.  Imatinib Drug Market- Company Profiles – (Overview, Product Portfolio, Financials, Developments)
9.1    Company 1
9.2    Company 2
9.3    Company 3
9.4    Company 4
9.5    Company 5
9.6    Company 6
9.7    Company 7
9.8    Company 8
9.9    Company 9
9.10    Company 10